Vyvanse vs Adderall XR

MEDICATION COMPARISON · FROM FDA LABELS AND HEAD-TO-HEAD STUDIES

Reviewed by Tariq Halim, MD · Last medical review: October 29, 2026 · Editorial policy

Vyvanse and Adderall XR are both FDA-approved ADHD medicines. Vyvanse contains lisdexamfetamine dimesylate and Adderall XR contains dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate. No head-to-head trial compares them, so this page compares label facts only and does not rank them. Facts below come from each product’s FDA label.

Side-by-side facts (from each FDA label)

Each cell is copied from that product’s key facts, which cite its current FDA prescribing information. Durations and doses come from each product’s own label studies; they are not a head-to-head comparison.

VyvanseAdderall XR
Drug classCNS Stimulant · AmphetaminesCNS Stimulant · Amphetamines
Active ingredientlisdexamfetamine dimesylatedextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate
FDA-approved agesADHD: 6 years and older; BED: adults6 years and older (children, adolescents, adults)
Form and strengthsCapsule; chewable tablet; Capsules: 10, 20, 30, 40, 50, 60, 70 mg
Chewable tablets: 10, 20, 30, 40, 50, 60 mg
Extended-release capsule; 5, 10, 15, 20, 25, 30 mg capsules
Usual dose and maximum (label)Start 30 mg once daily in the morning; maximum 70 mg/day.Ages 6–12: start 10 mg once daily, maximum 30 mg/day; ages 13–17: start 10 mg/day; adults: 20 mg/day.
Duration (label)Benefit through 12–13 hours in children and up to 14 hours in adults in label studies.Once daily on awakening; the label gives no duration in hours (morning and afternoon benefit in studies; peak about 7 hours).
DEA scheduleSchedule II controlled substance (CII)Schedule II controlled substance (CII)
GenericGeneric available (see Generic manufacturers)Generic available (see Generic manufacturers)
Label datePrescribing Information revised 04/2026 (DailyMed)Prescribing Information revised 04/2026 (DailyMed)
Availability (site status, Oct 2026)FDA shortage listed · brand availableBrand available (ASHP)

Main differences in plain words

  • Vyvanse contains lisdexamfetamine dimesylate; Adderall XR contains dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate.
  • Form: Vyvanse: capsule or chewable tablet; Adderall XR: extended-release capsule.
  • Controlled status: both: Schedule II controlled substance (CII).
  • Generic: Vyvanse: Generic available; Adderall XR: Generic available.

What studies compare them

No direct comparison. No head-to-head trial of Vyvanse and Adderall XR is in this site’s verified evidence base, so this page does not say that one works better than the other. The studies below give context only.

  • Randomized controlled trial

    Lisdexamfetamine (Vyvanse)

    In a classroom crossover study of 52 children aged 6–12, lisdexamfetamine improved attention, behavior and math performance compared with placebo, with side effects similar to Adderall XR.

    Adderall XR was a reference arm in this study, not a formal comparison, so it does not show which works better.

    Phase 2 crossover, n=52: LDX 30/50/70 mg vs placebo, MAS XR reference. SKAMP-D/A, PERMP and CGI-I improved; AEs similar for both actives.

    Biederman J, Boellner SW, Childress A, et al. (2007). Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62(9):970-6. DOI · PubMed 17631866

  • Network meta-analysis

    ADHD medicines (class)

    A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.

    This analysis compares amphetamines with other medicine classes. It does not separate individual amphetamine products such as Vyvanse and Adderall XR.

    Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.

    Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).

    Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390

Switching between them (label)

What each FDA label says about starting it after another medicine. Switch the clinician view on to see the full label wording and any dose tables. More in the switching guide.

Vyvanse (label section 2.2, Prescribing Information, revised 04/2026): Vyvanse capsules and chewables can be swapped at the same strength.

Vyvanse capsules and chewable tablets can be substituted unit-per-unit and mg-per-mg (for example, a 30 mg capsule for a 30 mg chewable tablet).

Adderall XR (label section 2.2, Prescribing Information, revised 04/2026): From Adderall tablets taken in divided doses, the label allows the same total daily amount as one Adderall XR dose.

Based on bioequivalence data, patients taking divided doses of immediate-release Adderall (for example, twice daily) may be switched to Adderall XR at the same total daily dose once daily, then titrated weekly.

Adderall XR (label section 2.3–2.5, Prescribing Information, revised 04/2026): From other medicines, Adderall XR starts at the usual starting dose.

Patients switching from another medication start like new patients: 10 mg/day (ages 6–17) or 20 mg/day (adults).

For clinicians

Label facts are from each product’s current prescribing information (Vyvanse: revised 04/2026; Adderall XR: revised 04/2026). Evidence summaries show the study detail and funding; comparative statements are limited to head-to-head trials, analyses of them and network meta-analyses. Indirect comparisons (for example, matching-adjusted indirect comparisons) are not used for efficacy claims.

Talk to your prescriber. These two medicines are not interchangeable at the same dose unless a label says so. Bring this page to your appointment if it helps, but do not change, stop or swap medicines on your own.

Frequently asked questions

What is the difference between Vyvanse and Adderall XR?

Vyvanse contains lisdexamfetamine dimesylate (capsule or chewable tablet); Adderall XR contains dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate (extended-release capsule). Vyvanse: Schedule II controlled substance (CII). Adderall XR: Schedule II controlled substance (CII). The side-by-side table on this page lists approved ages, doses, duration and generic status from each label.

Is Vyvanse more effective than Adderall XR?

No head-to-head trial of Vyvanse and Adderall XR is in this site’s verified evidence base, so there is no direct evidence that one works better. Network meta-analyses compare medicine classes, not these two products. Both are FDA-approved for ADHD in the ages shown on their labels.

Which lasts longer, Vyvanse or Adderall XR?

Per the labels: Vyvanse: Benefit through 12–13 hours in children and up to 14 hours in adults in label studies. Adderall XR: Once daily on awakening; the label gives no duration in hours (morning and afternoon benefit in studies; peak about 7 hours). These figures come from separate label studies, not from one study comparing the two.

Can you switch from Vyvanse to Adderall XR?

Neither label gives a milligram conversion between these two products. Vyvanse label: Vyvanse capsules and chewable tablets can be substituted unit-per-unit and mg-per-mg (for example, a 30 mg capsule for a 30 mg chewable tablet). Adderall XR label: Based on bioequivalence data, patients taking divided doses of immediate-release Adderall (for example, twice daily) may be switched to Adderall XR at the same total daily dose once daily, then titrated weekly. Patients switching from another medication start like new patients: 10 mg/day (ages 6–17) or 20 mg/day (adults). Any switch is planned and adjusted by the prescriber.

Are Vyvanse and Adderall XR available as generics?

Vyvanse: Generic available. Adderall XR: Generic available. Current supply is tracked on the availability tracker page.

Sources

  • Takeda Pharmaceuticals America, Inc. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, CII. Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
  • Takeda Pharmaceuticals America, Inc. Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII. Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
  • Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970-6. PubMed
  • Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PubMed
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. Do not start, stop, switch or change the dose of a medication without your prescriber. See the medical disclaimer.
Back to top